Diferansiye Tiroid Kanserlerinde Cerrahi Prosedürler

Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973–2002. JAMA. 2006;295(18):2164–2167.

Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26(1):1–133.

Cabanillas ME, McFadden DG, Durante C. Thyroid cancer. Lancet. 2016;388(10061):2783–2795.

Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19(11):1167–1214.

Tuttle RM, Leboeuf R, Shaha AR. Risk-adapted management of thyroid cancer: a new paradigm. Thyroid. 2010;20(6):577–583.

Pacini F, Schlumberger M, Dralle H, et al. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol. 2006;154(6):787–803.

Barczyński M, Konturek A, Stopa M, et al. Randomized clinical trial of visualization versus neuromonitoring of recurrent laryngeal nerves during thyroidectomy. Br J Surg. 2009;96(3):240–246.

Lee KE, Koo do H, Kim SJ, et al. Robot-assisted (Da Vinci) thyroid surgery: experience with the first 30 patients. Surg Laparosc Endosc Percutan Tech. 2009;19(3):e71–75.

Kim SW, Lee HS, Lee KD, et al. Intraoperative parathyroid gland identification using near-infrared autofluorescence imaging. J Clin Endocrinol Metab. 2016;101(12):4646–4652.

Hundahl SA, Fleming ID, Fremgen AM, et al. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985–1995. Cancer. 1998;83(12):2638–2648.

Baloch ZW, LiVolsi VA. Follicular-patterned lesions of the thyroid: the bane of the pathologist. Am J Clin Pathol. 2002;117(1):143–150.

Ito Y, Miyauchi A, Kihara M, et al. Risk-adapted management of thyroid cancer. Endocr J. 2013;60(1):1–13.

Yoon YH, Kim YJ, Jung TS, et al. Vascular invasion in follicular thyroid carcinoma: pathologic criteria and prognostic significance. Am J Surg Pathol. 2010;34(8):1159–1164.

Schlumberger M, Catargi B, Borget I, et al. Strategies of radioiodine ablation in patients with low-risk thyroid cancer. N Engl J Med. 2012;366(18):1663–1673.

Kloos RT, Mazzaferri EL, Braverman LE, et al. Preoperative imaging for thyroid cancer. Endocrinol Metab Clin North Am. 2008;37(2):389–403.

Sun H, Liu J, Zhang D, et al. Transoral endoscopic thyroidectomy vestibular approach (TOETVA): indications, techniques and results. Gland Surg. 2021;10(5):1655–1663.

Wells SA Jr, Asa SL, Dralle H, et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid. 2015;25(6):567–610.

Kloos RT, Eng C, Evans DB, et al. Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid. 2009;19(6):565–612.

Pacini F, Castagna MG, Cipri C, et al. Medullary thyroid carcinoma: clinical features and management. Endocrinol Metab Clin North Am. 2008;37(2):481–496.

Schlumberger M, Bastholt L, Dralle H, et al. 2009 European thyroid cancer taskforce guidelines for the management of advanced medullary thyroid cancer. Eur J Endocrinol. 2012;166(1):139–146.

Moley JF. Medullary thyroid carcinoma: management of lymph node metastases. J Natl Compr Canc Netw. 2010;8(5):549–556.

Ito Y, Miyauchi A, Kudo T, et al. Prophylactic modified radical neck dissection for medullary thyroid carcinoma: is it justified? World J Surg. 2013;37(2):289–295.

Kim WW, Yoo JE, Jeong J, et al. Comparison of surgical outcomes between robotic and open surgery for medullary thyroid carcinoma. J Surg Oncol. 2015;112(6):663–668.

Kandil E, Alabbas H, Noureldine SI, et al. Intraoperative adjuncts for the detection of medullary thyroid cancer: a review. Gland Surg. 2015;4(1):63–69.

Machens A, Dralle H. Genetic screening in medullary thyroid cancer: when and how? Nat Rev Endocrinol. 2013;9(9):558–566.

Smallridge RC, Ain KB, Asa SL, et al. American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer. Thyroid. 2012;22(11):1104–1139. doi:10.1089/thy.2012.0205

Molinaro E, Romei C, Biagini A, et al. Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies. Nat Rev Endocrinol. 2017;13(11):644–660. doi:10.1038/nrendo.2017.76

Bible KC, Kebebew E, Brierley J, et al. 2021 American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer. Thyroid. 2021;31(3):337–386. doi:10.1089/thy.2020.0944

Limberg J, Ullmann TM, Stefanova D, et al. Surgical resection improves survival in patients with anaplastic thyroid cancer: analysis of the National Cancer Database. Thyroid. 2020;30(5):731–740. doi:10.1089/thy.2019.0596

Iyer PC, Dadu R, Gule-Monroe MK, et al. Salvage kinase inhibitor therapy in anaplastic thyroid cancer. J Clin Endocrinol Metab. 2018;103(3):1311–1320. doi:10.1210/jc.2017-02427

Foote RL, Molina JR, Kasperbauer JL. Anaplastic thyroid cancer: treatment with intensive combined modality therapy. Head & Neck. 2010;32(10):1271–1278. doi:10.1002/hed.21295

Subbiah V, Hu MI, Wirth LJ, et al. BRAF‐targeted therapy in advanced anaplastic thyroid cancer. Thyroid. 2018;28(7):945–951. doi:10.1089/thy.2017.0665

DeLellis RA, Lloyd RV, Heitz PU, Eng C. Pathology and genetics of tumours of endocrine organs. In: World Health Organization Classification of Tumours. 3rd ed. Lyon: IARC Press; 2004. p. 49–55.

Ganly I, Wang L, Tuttle RM, et al. Invasion rather than nuclear features correlates with outcome in Hurthle cell carcinoma of the thyroid. Thyroid. 2014;24(3):408–413. doi:10.1089/thy.2013.0181

Nixon IJ, Whitcher MM, Palmer FL, et al. The impact of distant metastases at presentation on prognosis in patients with Hurthle cell carcinoma. Ann Surg Oncol. 2012;19(8):2616–2622. doi:10.1245/s10434-012-2280-6

Ibrahimpasic T, Ghossein R, Carlson DL, et al. Undifferentiated (anaplastic) thyroid carcinoma: a population-based study of incidence and outcomes. Thyroid. 2016;26(5):726–734. doi:10.1089/thy.2015.0351

Nixon IJ, Coca-Pelaz A, Kaleva AI, et al. Metastasis to the thyroid gland: a critical review. Ann Surg Oncol. 2017;24(6):1533–1539. doi:10.1245/s10434-016-5683-3

Cibas ES, Ali SZ. The Bethesda System for Reporting Thyroid Cytopathology. Am J Clin Pathol. 2009;132(5):658–665. doi:10.1309/AJCPPHLWMI3JV4LA

Dionigi G, Boni L, Rovera F, et al. Neuromonitoring in thyroid surgery. Int J Surg. 2008;6 Suppl 1:S83–S85. doi:10.1016/j.ijsu.2008.12.004

Zafereo M, Yu T, Bell D, et al. Optimal surgery for papillary thyroid carcinoma: Complete thyroidectomy versus lobectomy. Curr Opin Oncol. 2019;31(1):1–7.

Honings J, Stephen AE, Marres HA, Gaissert HA. The management of thyroid carcinoma invading the larynx or trachea. Laryngoscope. 2010;120(4):682–689. doi:10.1002/lary.20826

Smallridge RC, Copland JA. Anaplastic thyroid carcinoma: pathogenesis and emerging therapies. Clin Oncol (R Coll Radiol). 2010;22(6):486–497. doi:10.1016/j.clon.2010.03.005

Lee J, Nah KY, Kim RM, et al. Differences in postoperative outcomes, function, and cosmesis: Open versus robotic thyroidectomy. Surg Endosc. 2010;24(12):3186–3194. doi:10.1007/s00464-010-1113-0

Tae K, Ji YB, Song CM, et al. Robotic and endoscopic thyroid surgery in patients with thyroid carcinoma. Ann Surg Oncol. 2012;19(1):133–139. doi:10.1245/s10434-011-1920-6

Tuttle RM, Tala H, Shah J, et al. Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine therapy. J Clin Endocrinol Metab. 2010;95(9):4359–4365.

Momesso DP, Tuttle RM. Update on differentiated thyroid cancer follow-up. Best Pract Res Clin Endocrinol Metab. 2014;28(4):497–505.

Durante C, Montesano T, Attard M, et al. Long-term surveillance of differentiated thyroid cancer patients with undetectable thyroglobulin and negative imaging. J Clin Endocrinol Metab. 2012;97(8):2749–2753.

Pacini F, Molinaro E, Agate L, et al. Monitoring treatment of differentiated thyroid carcinoma. Endocr Relat Cancer. 2003;10(3):383–389.

Spencer CA, Takeuchi M, Kazarosyan M, et al. Serum thyroglobulin autoantibodies: prevalence, influence on assay sensitivity, and potential clinical utility. Clin Chem. 1998;44(12):250–257.

Papini E, Guglielmi R, Bianchini A, et al. Risk of malignancy in nonpalpable thyroid nodules: Predictive value of ultrasound and color-Doppler features. J Clin Endocrinol Metab. 2002;87(5):1941–1946.

Leboulleux S, Schroeder PR, Busaidy NL, et al. Assessment of the incremental value of diagnostic whole-body scan in the follow-up of patients with papillary and follicular thyroid cancer. J Clin Endocrinol Metab. 2009;94(5):1753–1759.

Schlumberger M, Leboulleux S. Current practice in patients with differentiated thyroid cancer. Nat Rev Endocrinol. 2021;17(3):176–188.

Xing M, Haugen BR, Schlumberger M. Progress in molecular-based management of differentiated thyroid cancer. Lancet. 2013;381(9871):1058–1069.

Filetti S, Durante C, Hartl D, et al. Thyroid cancer: ESMO Clinical Practice Guidelines. Ann Oncol. 2019;30(12):1856–1883.

Fagin JA, Wells SA Jr. Biologic and clinical perspectives on thyroid cancer. N Engl J Med. 2016;375(11):1054–1067.

Nixon IJ, Wang LY, Palmer FL, et al. Outcomes for patients with poorly differentiated thyroid carcinoma: An institutional review. Ann Surg Oncol. 2016;23(4):1276–1284.

Godballe C, Madsen AR, Pedersen HB, et al. Pathological and functional outcome after total thyroidectomy in patients with differentiated thyroid cancer. Eur Arch Otorhinolaryngol. 2013;270(8):2325–2329.